Matinas BioPharma Holdings, Inc. (MTNB) Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Matinas BioPharma Holdings, Inc. NYSE:MTNB Healthcare · Biotechnology
AH Close $1.66 +0.00% vs close
AH Close $1.66 +0.00% vs close
All Press Release SEC Filings News
SEC Filing ● Major ⚠ 2
MTNB: 8-K · reverse split
Matinas BioPharma effected a one-for-fifteen reverse stock split effective 12:01 a.m. ET on September 28, 2026, via a Certificate of Amendment filed with Delaware on September 25, 2026. The split consolidates every 15 shares into one, with fractional shares cashed out at the pre-split adjusted closing price, and the stock began trading split-adjusted on NYSE American on September 28.
SEC 8-K • 28d ago SEC Filing ● Major ⚠ 3
MTNB: 8-K · reverse split
Matinas BioPharma Holdings' Board approved a one-for-fifteen (1:15) reverse stock split of its common stock, effective 12:01 a.m. ET on September 28, 2026. Shares will begin trading on a split-adjusted basis under the existing symbol MTNB on NYSE American when the market opens that day, and the CUSIP will change to 576810 402.
The split falls under blanket stockholder authorization granted at the June 23, 2025 annual meeting, which permitted up to two reverse splits at aggregate ratios ranging from 1:2 to 1:199 without further approval. No fractional shares will be issued — holders receive proportional cash payments — and each stockholder's percentage ownership and voting power remain essentially unchanged.
The company explicitly warned there is no assurance the split will preserve its NYSE American listing, framing this as a listing-compliance move. A 1:15 consolidation in a micro-cap biotech is typically a distress signal, and investors should watch for continued bid-price deficiency risk after the effective date.
SEC 8-K • 1mo ago Press Release ⚠ 3
GH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility Output
GH Power, the private Canadian clean-energy company proposing to combine with Matinas BioPharma (NYSE American: MTNB), signed its first commercial hydrogen offtake agreement with Change Energy Engineering and its subsidiary Hone Inc. for output from the Hamilton, Ontario facility.
Terms call for supply of up to 1,000 kilograms of hydrogen per day, with an initial term of two years after commercial operations commence; deliveries are on a best-efforts basis during an initial period of intermittent availability, and no dollar value or pricing was disclosed.
For MTNB holders, the deal is the first contracted revenue validation of GH Power's aluminum-water reactor platform ahead of the pending business combination, whose Form F-4 has not yet been filed and whose closing conditions include GH Power financing of at least $15.0 million gross, shareholder approvals, and Ontario court approvals.
• 1mo ago AI analysis › Press Release ⚠ 5
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Matinas BioPharma received an NYSE American notice dated August 31, 2026 stating it fails the continued listing standard requiring at least $2.0 million of stockholders' equity for companies with recent operating losses. The company reported $1.8 million of stockholders' equity as of June 30, 2026 and has recorded losses from continuing operations and/or net losses in each of its five most recent fiscal years.
This adds a third active deficiency — Matinas was already non-compliant with Sections 1003(a)(ii) and 1003(a)(iii). Its compliance plan, accepted by the exchange on May 4, 2026, runs through October 2, 2027; failing to regain compliance or to make plan-consistent progress by then can trigger delisting proceedings, subject to appeal.
Trading is unaffected for now: the stock remains listed with the .BC noncompliance indicator attached, and the notice does not affect operations or SEC reporting. For a clinical-stage biotech whose lead asset MAT2203 is still pre-commercial, rebuilding equity above the threshold most likely implies a dilutive financing ahead.
• 1mo ago AI analysis › SEC Filing ⚠ 5
MTNB: 425 · acquisition merger
Matinas BioPharma (NYSE American: MTNB) filed a Form 425 containing a sponsored Wall Street Wire report on its previously announced business combination with GH Power Inc., a Canadian critical minerals and clean energy company. The transaction is expected to close in the fourth quarter of 2026 and would take GH Power public through a newly formed Ontario parent, GH Power International, listed on NYSE American.
GH Power's reactor technology converts recycled or primary aluminum and water into fuel-cell-grade hydrogen, high-purity aluminum oxide, and thermal energy from a single system, with claimed operational demonstration at its Hamilton, Ontario pilot facility. The company is pre-revenue, and the article frames its story around AI data center power demand and aluminum's placement on the USGS 2025 critical minerals list.
Closing remains conditioned on Matinas stockholder approval, GH Power securityholder approval, Ontario court approvals, effectiveness of a Form F-4 that has not yet been filed, a GH Power financing producing gross proceeds of at least $15.0 million, GHP International qualifying as a foreign private issuer, and NYSE American listing.
The report is paid promotion: Matinas pays Wall Street Wire $6,500 per month in cash compensation, the content is expressly labeled a form of paid advertising, and the cited third-party market data is not independently verified.
SEC 425 • 2mo ago SEC Filing ● Critical ⚠ 7
MTNB: 10-Q · periodic report
Matinas BioPharma's Q2 2026 10-Q carries substantial-doubt going-concern language: cash fell to $761,000 from $4.0 million at year-end 2025, the six-month net loss was $3.2 million, and the accumulated deficit reached $214.0 million. Management states existing cash is insufficient to fund operations for at least the next twelve months.
Post-quarter, Matinas signed a Business Combination Agreement with Canada's GH Power under which the company becomes a wholly owned subsidiary of a new pubco, with current Matinas equityholders left with roughly 9% of the combined company (0.1 Pubco share per Matinas share; Matinas valued at $24.7 million vs. GH Power at $250 million). Separately, Azurity Pharmaceuticals agreed to buy subsidiary Nanotechnologies, owner of lead asset MAT2203, for up to $21.5 million in cash plus a mid-single-digit royalty.
The company raised about $2.9 million after quarter-end via a $575K Series D preferred financing and a $2.3 million warrant inducement that reset 2025 warrant and Series C conversion prices to $0.35, while BTIG terminated the $50 million ATM program, which still had $44.2 million of unused capacity.
Matinas is out of compliance with NYSE American stockholders'-equity standards, but its remediation plan was accepted with a deadline of October 2, 2027; continued listing is also a closing condition of the pending deals, and failure to close them could force a wind-down or dissolution.
SEC 10-Q • 2mo ago AI analysis › SEC Filing ⚠ 5
MTNB: 425 · acquisition merger
Matinas BioPharma Holdings filed a Rule 425 communication containing a Bloomberg article and CEO transcript, posted August 4, 2026 by Market One Media Group on behalf of GH Power, publicizing the business combination agreement the companies signed on July 10, 2026.
Under the deal, a newly formed Ontario corporation expected to be named GH Power International Inc. would become the public parent of both companies, with GH Power shareholders holding approximately 91% and existing Matinas stockholders approximately 9%, subject to adjustment. The combined company is expected to list on NYSE American, with closing targeted for Q4 2026 and conditioned on shareholder and securityholder approvals, a GH Power financing of at least $15.0 million gross proceeds, and listing approval.
GH Power is a pre-revenue Ontario company building modular reactors that convert scrap metals and water into clean hydrogen, thermal energy, and high-purity alumina; it discloses a limited operating history and no material revenues. The Form F-4 registration statement for the transaction has not yet been filed, leaving closing contingent on multiple approvals and financing milestones.
SEC 425 • 2mo ago Press Release ⚠ 3
GH Power and TKMS Continue to Explore Clean Energy Collaboration in Support of Canada’s Future Patrol Submarine Project
GH Power, which is set to merge with Matinas BioPharma (MTNB), confirmed it is exploring a collaboration with TKMS to support the Canadian Patrol Submarine Project under a non-binding MOU.
The initiative aims to integrate GH Power's clean energy and advanced materials technologies into naval supply chains, potentially securing non-dilutive funding through Industrial and Technological Benefits.
The definitive merger agreement remains subject to closing conditions, including securing at least $15.0 million in gross proceeds, regulatory approvals, and shareholder consent.
• 2mo ago AI analysis › SEC Filing ⚠ 1
MTNB: 8-K · material agreement
Matinas BioPharma Holdings, Inc. disclosed that BTIG, LLC has terminated the company's At-The-Market Sales Agreement effective immediately as of July 23, 2026.
The original agreement, established in July 2020, provided the company with the capacity to sell up to $50 million in common stock through at-the-market offerings.
Matinas confirmed that it is not responsible for any termination penalties or additional expenses associated with ending the agreement.
SEC 8-K • 3mo ago SEC Filing
MTNB: 425 · other
Matinas BioPharma Holdings, Inc. filed a Form 425 with the SEC on July 21, 2026, identifying the company itself as the subject company. The filing was made pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934. The provided document includes only the header information and lacks the actual solicitation materials or exhibit text required to summarize the content of the communication. As a result, the specific details regarding the purpose or subject matter of the filing are not available in the input.
SEC 425 • 3mo ago SEC Filing ● Major ⚠ 3
MTNB: 425 · acquisition merger
Matinas BioPharma entered into a definitive business combination agreement with GH Power Inc., a private company specializing in modular reactor technology for green hydrogen production. The transaction will result in the creation of a new parent company, GH Power International, which is expected to list on the NYSE American upon closing.
Under the current terms, existing GH Power shareholders are expected to own approximately 91% of the combined entity, while existing Matinas stockholders will retain approximately 9% ownership. This structure effectively represents a reverse merger and a change of control, resulting in significant dilution for current Matinas investors.
The transaction is anticipated to close in the fourth quarter of 2026, subject to conditions including shareholder approvals, court approval, and the completion of a PIPE financing raising at least $15.0 million in gross proceeds.
SEC 425 • 3mo ago Press Release ● Critical ⚠ 2
GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma
Matinas BioPharma (MTNB) entered into a definitive business combination agreement with GH Power, creating a new publicly traded company focused on clean energy and critical materials.
Upon closing, GH Power equityholders will own approximately 91% of the combined entity, while Matinas shareholders will retain about 9%; concurrently, Matinas will sell its LNC technology and MAT2203 assets to Azurity Pharmaceuticals for $4 million upfront plus potential milestones.
The transaction is contingent upon a PIPE financing of at least $15 million and is expected to close in the fourth quarter of 2026, subject to stockholder and regulatory approvals.
• 3mo ago AI analysis › Press Release ● Critical ⚠ 3
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Matinas BioPharma agreed to merge with GH Power in a business combination that will transform the company into a publicly traded clean energy and green hydrogen entity. Existing Matinas shareholders will own approximately 9% of the combined company, GHP International, while GH Power equityholders will own 91%, with each share of Matinas common stock converting into 0.1 shares of GHP International.
Concurrently, the company entered a definitive agreement to sell its lead product candidate MAT2203 and lipid nano-crystal (LNC) technology platform to Azurity Pharmaceuticals for $4.0 million upfront, plus up to $17.5 million in milestone payments and royalties.
To support these transactions, Matinas closed $575,000 in gross proceeds from a Series D financing and approximately $2.6 million from a warrant inducement exercise, with proceeds earmarked for working capital and general corporate purposes.
• 3mo ago AI analysis › Press Release ⚠ 3
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance
Matinas BioPharma received a non-compliance notice from the NYSE American because it failed to meet continued listing standards regarding stockholders' equity.
As of March 31, 2026, the company held $3.02 million in equity, below the $4.0 million requirement, and has reported losses in five of its most recent fiscal years.
The exchange accepted the company's plan to cure the deficiency, granting a compliance period through October 2, 2027, though failure to meet standards by that date could result in delisting.
• 4mo ago AI analysis › SEC Filing ⚠ 3
MTNB: S-3 · shelf registration
Matinas BioPharma Holdings, Inc. has filed a replacement registration statement on Form S-3 to extend the offering period for up to $150 million of securities. This shelf filing allows the company to offer common stock, preferred stock, debt securities, warrants, subscription rights, or units on a delayed or continuous basis.
The company intends to use the net proceeds from any future sales for working capital and general corporate purposes. However, the actual amount that can be sold is limited because the aggregate market value of the company's public float is approximately $5.6 million. Consequently, the company cannot sell securities with a value exceeding one-third of this public float in any 12-month period.
The replacement filing was made pursuant to Rule 415(a)(6) to carry forward unsold securities from a prior registration statement. As of June 15, 2026, the last reported sales price of the company's common stock was $0.75 per share.
SEC S-3 • 4mo ago AI analysis › Press Release
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
globenewswire.com • 6mo ago 
